An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2017
Price : $35 *
At a glance
- Drugs Atuveciclib (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Bayer
- 31 Aug 2018 Biomarkers information updated
- 22 Nov 2016 Status changed from active, no longer recruiting to completed.
- 05 Oct 2016 Planned End Date changed from 1 Mar 2017 to 1 Nov 2016.